Xiawei Wu

Dr. Xiawei Wu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Cancer Medicine
Verified
Journal Article
Open access
YSYongji Sun
Yongji Sun
CHChaowen Hu
Chaowen Hu
SHSien Hu
Sien Hu
HXHongxia Xu
Hongxia Xu
JGJiali Gong
Jiali Gong
YWYulian Wu
Yulian Wu
Introduction: Individuals who develop new‐onset diabetes have been identified as a high‐risk cohort for pancreatic cancer (PC), exhibiting an incidence rate nearly 8 times higher than the general population. Hence, the targeted screening of this specific cohort presents a promising opportunity for early pancreatic cancer detection. We aimed to develop and validate a novel model capable of identifying high‐risk individuals among those with new‐onset diabetes. Methods: Employing the UK Biobank cohort, we focused on those developing new‐onset diabetes during follow‐up. Genetic and clinical characteristics available at registration were considered as candidate predictors. We conducted univariate regression analysis to identify potential indicators and used a 5‐fold cross‐validation method to select optimal predictors for model development. Five machine learning algorithms were used for model development. Results: Among 12,735 patients with new‐onset diabetes, 100 (0.8%) were diagnosed with PC within 2 years. The final model (area under the curve, 0.897; 95% confidence interval, 0.865–0.929) included 5 clinical predictors and 24 single nucleotide polymorphisms. Two threshold cut‐offs were established: 1.28% and 5.26%. The recommended 1.28% cut‐off, based on model performance, reduces definitive testing to 13% of the total population while capturing 76% of PC cases. The high‐risk threshold is 5.26%. Utilizing this threshold, only 2% of the population needs definitive testing, capturing nearly half of PC cases. Conclusions: We, for the first time, combined clinical and genetic data to develop and validate a model to determine the risk of pancreatic cancer in patients with new‐onset diabetes using machine learning algorithms. By reducing the number of unnecessary tests while ensuring that a substantial proportion of high‐risk patients are identified, this tool has the potential to improve patient outcomes and optimize healthcare sources.

30 March 2023 in Frontiers in Surgery
Verified
Journal Article
Open access
Yunxiang ZhouYunxiang Zhou
Yunxiang Zhou
LDLinping Dong
Linping Dong
LDLinyun Dai
Linyun Dai
SHSien Hu
Sien Hu
YSYongji Sun
Yongji Sun
XWXiawei Wu
Xiawei Wu
Background: Hepatoid adenocarcinoma of the stomach (HAS) is a highly malignant subtype of gastric carcinoma with specific clinicopathological features and extremely poor prognosis. We present an exceedingly rare case of complete response after chemo-immunotherapy.Case Description: A 48-year-old woman with highly elevated serum alpha-fetoprotein (AFP) level was found to have HAS verified by pathological examination based on gastroscopy. Computed tomography scan was done and TNM staging of the tumor was T4aN3aMx. Programmed cell death ligand-1 (PD-L1) immunohistochemistry was performed, revealing a negative PD-L1 expression. Chemo-immunotherapy including oxaliplatin plus S-1 and PD-1 inhibitor terelizumab was given to this patient for 2 months until the serum AFP level decreased from 748.5 to 12.9 ng/mL and the tumor shrank. D2 radical gastrectomy was then performed and histopathology of the resected specimen revealed that the cancerous cells had disappeared. Pathologic complete response (pCR) was achieved and no evidence of recurrence has been found after 1 year of follow-up.Conclusions: We, for the first time, reported an HAS patient with negative PD-L1 expression who achieved pCR from the combined chemotherapy and immunotherapy. Although no consensus has been reached regarding the therapy, it might provide a potential effective management strategy for HAS patient.

25 July 2025 in Advanced Science
Verified
Journal Article
Open access
ZFZengyu Feng
Zengyu Feng
JLJianyao Lou
Jianyao Lou
CLChuanshuai Lin
Chuanshuai Lin
HYHaocheng Yu
Haocheng Yu
YTYuheng Tu
Yuheng Tu
YWYulian Wu
Yulian Wu
Elevated blood glucose levels may serve as an early indicator of underlying pancreatic cancer. Discriminating between pancreatic cancer‐associated new‐onset diabetes (PCAND) and new‐onset type 2 diabetes mellitus (T2DM) holds promise for enabling an earlier diagnosis of pancreatic cancer. Nevertheless, the absence of effective biomarkers for distinguishing PCAND from the more prevalent new‐onset T2DM persists, primarily because of the elusive pathogenesis of PCAND. In this study, the intricate intercellular communication is comprehensively elucidated through single‐cell RNA sequencing. The findings identified Midkine (MDK) as a potential mediator of the interaction between tumor and beta cells. MDK, which originated from pancreatic ductal adenocarcinoma cells, exerted deleterious effects on paraneoplastic beta cells by binding to the SDC4 receptor on the beta cell surface and subsequently downregulating the Ras signaling pathway, thereby impairing insulin production and secretion. Notably, the plasma levels of MDK are higher in patients with PCAND than in those with T2DM. In conclusion, MDK has emerged as a pivotal driver of PCAND pathogenesis and may function as a blood‐based biomarker for discriminating between PCAND and T2DM in populations with new‐onset diabetes, thereby facilitating the advancement of early detection strategies for pancreatic cancer.

12 November 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
XHXiying Huang
Xiying Huang
RLRuizi Lin
Ruizi Lin
YXYixin Xiao
Yixin Xiao
ZMZihan Ma
Zihan Ma
HXHongxia Xu
Hongxia Xu
XWXiawei Wu
Xiawei Wu
Grade 2 subclinical hypothyroidism (G2SCH) is associated with an increased risk of various diseases but is rarely detected before symptom onset. This study aims to develop a machine learning-based prediction model for G2SCH using routine physical examination data. 57,539 samples were collected from one institution for training and 33,880 from another one for testing. Three feature-selecting methods were employed, while five machine learning algorithms were utilized. SHapley Additive exPlanation (SHAP) index of selected features were calculated. Area under curve (AUC), sensitivity and specificity were used to evaluate models. Our results demonstrate that the logistic regression model, using features selected by LASSO under a 65:35 SMOTENC ratio, achieved robust predictive performance with an AUC of 0.870 (95% CI: 0.834, 0.906), sensitivity of 86.8%, and specificity of 70.8%. We developed a high-performance machine learning model for G2SCH prediction based on physical examination data, enabling timely referral and appropriate treatment of G2SCH patients.

7 August 2023 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
YCYahong Chen
Yahong Chen
XYXueqing Yang
Xueqing Yang
XWXiawei Wu
Xiawei Wu

24 March 2025 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
HLHai-Yan Lv
Hai-Yan Lv
MLMei-Xuan Liu
Mei-Xuan Liu
WHWen-Ting Hong
Wen-Ting Hong
XWXiawei Wu
Xiawei Wu
BACKGROUND Primary hepatic neuroendocrine tumors (PHNETs) are extremely rare tumors originating from neuroendocrine cells. Due to lack of neuroendocrine symptoms and specific radiographic characteristics, PHNETs are challenging to differentiate from other liver tumors. CASE SUMMARY This case involved a 67-year-old male who was admitted with a discovered hepatic mass and a suspicious lung lesion. Primary hepatic carcinoma was initially speculated based on the characteristic magnetic resonance imaging findings. The patient underwent a laparoscopic right partial hepatectomy, and subsequent immunohistochemical examination revealed a HNET. To exclude other potential origins, a positron emission tomography-computed tomography scan and gastrointestinal endoscopy were performed, leading to a final diagnosis of PHNETs. Then we conducted a literature review using the PubMed database, identifying 99 articles and 317 cases related to PHNETs. The characteristics, diagnostic methods, and treatment of PHNETs have been described. Finally, we elaborate on the presumed origins, pathological grades, clinical features, diagnosed methods, and treatments associated with PHNETs. CONCLUSION The diagnosis of PHNETs was primarily an exclusionary process. A definitive diagnosis of PHNETs relied mainly on immunohistochemical markers (chromogranin A, synaptophysin, and cluster of differentiation 56) and exclusion of primary foci in other organs. Radical surgery was the preferred treatment for early-stage tumors.